Recently, the Sichuan Provincial Health Commission officially released the '2024 Sichuan Clinical Specialty Medical Services and Quality Report'.
In the fierce competition among urology departments of 166 participating hospitals across the province, the Urology Department of Sichuan Cancer Hospital, led by Director Liao Hong, Chairman of the Urology Committee of Chengdu High-Tech Medical Association, successfully achieved the highest rating—A++—due to its outstanding medical quality, exceptional technical expertise, leading service standards, and superior comprehensive management efficiency.
This not only signifies that the Department of Urology at Sichuan Cancer Hospital has firmly established itself as a leading force in the province's urological specialty, but also serves as an authoritative certification and the highest accolade for the department's comprehensive strength and core competitiveness!
The Department of Urology at Sichuan Cancer Hospital has taken root in fertile soil since its establishment, undergoing generations of torch-passing and relentless efforts: In 2009, the department established an independent ward, marking the beginning of a new journey toward specialization and refinement; by 2018, it was recognized as a Class A Key Medical Discipline in Sichuan Province, with its disciplinary development receiving authoritative provincial recognition; in 2022, it was successfully selected for the Sichuan Provincial Clinical Key Specialty Construction Project, garnering significant attention for its development potential and prospects. Years of accumulated efforts have made it a model discipline. Today, the department has evolved into an academic highland and leader in the field of urology within the region: it serves as the chair unit of the Urology Committee of the Sichuan Geriatrics Association and the Urology Committee of the Chengdu High-Tech Medical Association, leading regional academic development.
As the leading unit of the Sichuan Collaborative Group for Urological Oncology under China Cancer Hospital and the leading unit of the Urological Oncology Quality Control Group under the Sichuan Provincial Health Commission's Quality Control Center for Tumor Diseases, it plays a core pivotal role in the field of MDT (Multidisciplinary Team) for urological oncology.
The designation as the MDT Excellence Center by the Urological Male Genital System Tumor Committee of the Chinese Anti-Cancer Association signifies that the comprehensive diagnosis and treatment capabilities for urological tumors have reached an advanced domestic level.
Over the years, the department has consistently adhered to the core principles of "meticulous technical research, service excellence, and safeguarding urinary health," striving to provide patients with precise, minimally invasive, efficient, safe, and personalized diagnostic and therapeutic services. It comprehensively covers all subspecialty fields of urogenital tumors, particularly leading the province in standardized, individualized, and minimally invasive (laparoscopic, robot-assisted) comprehensive diagnosis and treatment of urological tumors (renal cell carcinoma, bladder cancer, prostate cancer, etc.).
The facility is equipped with internationally advanced high-definition laparoscopic systems, flexible and rigid ureteroscopes, laser devices, and da Vinci surgical robots to ensure precision in surgical procedures.
Through continuous refinement of the MDT (Multidisciplinary Team) model and integration of optimal resources, our hospital has achieved sustained advancements in urological oncology diagnosis and treatment, with significant improvements in patient survival time and quality of life.
Meanwhile, the department places high emphasis on scientific research and innovation in the field of urological oncology, having led multiple national and provincial clinical research projects. The research achievements are abundant, providing solid evidence-based support for clinical practice.
The department boasts a highly ethical, technically proficient, experienced, and well-structured medical team, comprising renowned experts, discipline leaders, and mid-career and young core members.
In terms of academic leadership, we actively enhance the prevention, screening, diagnosis, treatment, and rehabilitation of urological tumors in the region through various forms such as popular science lectures, technical tours, professional training, and public welfare medical consultations.
While maintaining technical excellence, we emphasize warm-hearted services, implement patient-centered comprehensive management, prioritize humanistic care, provide personalized diagnosis and treatment plans as well as high-quality nursing services, and strive to enhance the patient experience.
Chengdu High-tech Medical Association has been steadily advancing alongside its various professional committees, dedicated to consolidating industry expertise, establishing collaborative platforms, and continuously supporting the development and construction of these committees.
On the occasion of the commencement of this new chapter, we extend our warmest congratulations to the Department of Urology at Sichuan Cancer Hospital!
We look forward to working closely with our member organizations and industry peers in the future.
Let us deepen collaboration, actively compete, and courageously explore in the fields of clinical diagnosis and treatment, academic research, technological innovation, and talent cultivation, jointly injecting strong and lasting 'new momentum' into the high-quality development of the health sector!
